Curis to Release Second Quarter 2011 Financial Results and Hold Conference Call on July 28, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)-- Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its second quarter financial results on Thursday, July 28, 2011 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. EDT to discuss: (i) vismodegib (GDC-0449, RG3616), a hedgehog pathway inhibitor under collaboration with Genentech, (ii) CUDC-101, CUDC-907, Debio 0932 and other network-targeted cancer programs, (iii) its financial results as of and for the three- and six-month periods ended June 30, 2011, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.

To access the live conference call, please call (800) 215-2410 from the United States or Canada or (617) 597-5410 from other locations, shortly before 9:00 A.M. EDT. The conference ID number is 30648998. The conference call can also be accessed on the Curis website at in the Investors section. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EDT, Thursday, August 4, 2011. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 47723201.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at


Curis, Inc.
Michael P. Gray, 617-503-6632
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Genetics  Oncology  Pharmaceutical